Navegando por Assunto "Neurologia"

Agora exibindo 1 - 4 de 4

Acesso aberto (Open Access)
Aspectos clínicos e epidemiológicos da infecção pelo HTLV em usuários do Centro de Testagem e Aconselhamento do município de Santarém- Pará
(Universidade Federal do Pará, 2014) BARBOSA, Richelma de Fátima Miranda; MARTINS, Luisa Caricio; http://lattes.cnpq.br/1799493244439769
Acesso aberto (Open Access)
Dor neuropática crônica hansenica: serie de casos clínicos com ênfase no diagnóstico e terapêutica com toxina botulínica tipo A
(Universidade Federal do Pará, 2014) SOUSA, Emanuel de Jesus Soares de; XAVIER, Marília Brasil; http://lattes.cnpq.br/0548879430701901
Neuropathic pain is a chronic pain syndrome is difficult to treat often affects patients with leprosy. Treatment advocates the use of analgesic, anti-inflammatory hormone or not, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without uniforms, and fully satisfactory results. OBJECTIVE: To describe patients with chronic neuropathic pain leprosy, clinical forms, damaged nerves, motor and sensory syndromes, clinical diagnosis, Electrodiagnostic, and evaluation of the WHOQOL - Bref, with emphasis on the treatment of chronic neuropathic pain using botulinum toxin type A (TxBA). METHODOLOGY: 15 patients with chronic neuropathic pain. We used specific protocol including clinical, demographic, DN4 protocol, analog scale (VAS), sensory evaluation, and motor electromyography and evaluation of the WHOQOL- Bref. Performed therapeutic intervention with botulinum toxin type A 100U BOTOX® administered subcutaneously. Patients were evaluated on days 0, 10 and 60, the WHOQOL - Bref was performed on days 0 and 60. RESULTS: The scores ranged from DN4 - 5 and 9, Analogue Scale VAS pain between 5 and 10, all patients experienced sensory changes, motor and electromyography in 01 cases there was complete pain relief in 60 days, others showed improvement in the first week with the return of symptoms with less intensity after this period, the WHOQOL - Bref comparing the moments before and after treatment with TxBA, all areas had an increase in QOL scale, areas with significant quality of life and physical. CONCLUSION: The patients had continuous, persistent refractory to standard treatment neuropathic pain of high intensity. Using TxBA proved to be a good therapeutic option in relieving the painful condition, with improved quality of life for these patients.
Acesso aberto (Open Access)
Incapacidades funcionais dos pacientes sororeativos ao HTLV com manifestações neurológicas do Núcleo de Medicina Tropical/UFPA
(Universidade Federal do Pará, 2010-03-23) BARBOSA, Richelma de Fátima Miranda; XAVIER, Marília Brasil; http://lattes.cnpq.br/0548879430701901
Acesso aberto (Open Access)
Prevalência de sintomas urinários em indivíduos portadores do Vírus Linfotrópico de Células T Humanas do tipo 1 (HTVL-1)
(Universidade Federal do Pará, 2014) CONSTANTE, Caroline Santos; CRESCENTE, José Ângelo Barletta; http://lattes.cnpq.br/5243773796185944
The human T-cells lymphotropic virus type 1 (HTLV-I) infects approximately 20 million people worldwide. It is mainly associated with adult T-cell leukemia/lymphoma (ATLL) and a neurological disease HLTV associated myelopathy/ tropical spastic paraparesis (HAM/TSP). The HAM/TSP causes motor abnormalities, weakness, increased tone in the lower limbs, urinary and erectile dysfunction. Studies show that there is a tendency of patients with HTLV-I to have some urinary symptoms. These symptoms persist not only in individuals with HAM/TSP, but also in individuals considered as asymptomatic carriers. This highlights the importance of studies that address the multitude of urinary symptoms in individuals with HTLV-I in order to deepen the scientific knowledge of the clinical progression of HTLV-I infected individuals, facilitate diagnosis, allow for earlier interventions and improve the quality of life and health of patients with HTLV-I. This research was aimed to determine the prevalence of urinary symptoms among individuals with HTLV-I with the specific objectives to describe the socio-demographic characteristics; identify the most frequent urinary symptoms reported; verify the association of the presence of urinary symptoms to neurological findings and analyze the impact on quality of life of urinary symptoms in individuals with HTLV-I. The study involved cross-sectional analysis involving 45 individuals with HTLV-I through the outpatient clinic at the NMT/UFPA. Through clinical neurological evaluation, the presence of urinary symptoms and impact assessment of urinary symptoms on quality of life by carriers HTLV-I was assessed applying the King's Health Questionnaire. The sample have had an average of 48.82 years of age, most were asymptomatic (64,44%), female (64,44%), married (64,44%), with primary education (53,33%) and without knowledge of its mode of infection (53,33%). The prevalence of urinary symptoms was 73,33% being 69% among patients with asymptomatic HTVL-I and 81,3% among individuals with HAM/TSP. The most common urinary symptoms were nocturia (71.11%), urinary urgency with incontinence (44.44%) and urinary urgency (42.22%). There was no association between neurological findings and the presence of urinary symptoms and the assessment of quality of life showed negative impact on seven of the nine areas covered by the questionnaire. High prevalence of urinary symptoms was found in individuals with HTLV-I, not only in individuals with HAM/TSP, but also in patients considered asymptomatic carriers. It is suggested that further studies with larger sample sizes and more accurate diagnostic tests to clarify development of these symptoms among asymptomatic carriers and its relationship with the worsening of myelopathy.